Current Research into Cures for Type-1 Diabetes

Teplizumab (sold as Tzield) was recently approved for use in people at-risk of diagnosis for T1D.  At risk meaning people who have two auto...

This blog covers three pieces of news which do not apply directly to cure focused research, but which I found interesting anyway. Tight Hone...

On 17-Nov-2022, The USA FDA approved Teplizumab.  This is the first drug ever approved in the United States which changes the course of Type...

Provention Bio is a small biotech company targeting several autoimmune diseases.  It has two drug candidates which target T1D: teplizumab (P...

Teplizumab is a proposed treatment which, if given to someone at-risk for type-1 diabetes (T1D), can delay or possibly prevent the onset of ...

I have blogged dozens of times on clinical trials run by TrialNet, but I've never discussed TrialNet as an organization, so this blog ...

Here are three recent updates on Teplizumab.  You can read my previous summary of this drug here: https://cureresearch4type1diabetes.blogspo...

This is another clinical trial using Teplizumab, but since this trial is more focused on AG019, I've put in a separate blog post from th...

As with previous years, the American Diabetes Association's annual scientific meeting is mostly about type-2 diabetes, and even the type...